文献速递帕金森病与运动障碍认知障碍与痴呆

帕金森病嗅黏膜神经元中α-突触核蛋白相关线粒体-Nrf2功能障碍

α-Synuclein-Related Mitochondria-Nrf2 Dysfunction in Parkinson's Disease Olfactory Mucosa.
PubMed 文献 · Ann Neurol · 2025-06-12

研究纳入41例帕金森病患者(24例新诊断未治疗,17例治疗中)和29例健康对照,通过鼻刷获取嗅黏膜神经元,检测线粒体网络与细胞保护反应。发现患者神经元积累α-突触核蛋白寡聚体,DJ-1表达持续降低,Nrf2/SOD-1通路下调且呈阶段特异性;多巴胺可增加Nrf2核转位。嗅黏膜神经元可重现帕金森病病理里程碑。

要点

  • 帕金森病患者嗅黏膜神经元积累α-突触核蛋白寡聚体并伴线粒体标志物分布异常。
  • DJ-1表达持续降低,Nrf2/SOD-1通路下调呈疾病阶段特异性。
  • 多巴胺可增加Nrf2核转位,提示其可能诱导该通路。

核心结论

  • 人源嗅黏膜神经元可重现帕金森病病理里程碑,展现α-突触核蛋白寡聚体、线粒体代谢与细胞保护反应的阶段特异性交互。
  • 线粒体功能障碍是治疗干预的主要靶点,并可能作为患者生物学分层的轴。
  • 嗅黏膜神经元具有作为生物标志物或模型的转化价值。

研究设计与样本

  • 研究纳入41例表型明确的帕金森病患者(24例新诊断未治疗,17例治疗中)和29例健康对照,经鼻刷获取嗅黏膜神经元。
  • 采用实时聚合酶链反应、免疫荧光和蛋白质印迹检测,并辅以SH-SY5Y神经元细胞实验。

主要发现

  • 帕金森病嗅黏膜神经元积累α-突触核蛋白寡聚体,伴随线粒体标志物COX IV和HSP60的亚细胞分布异常。
  • DJ-1在帕金森病嗅黏膜神经元中表达持续降低,提示线粒体功能障碍并解释Nrf2介导的细胞保护反应缺陷。
  • Nrf2/SOD-1通路在帕金森病嗅黏膜神经元中下调,但存在阶段特异性差异:新诊断患者Nrf2主要呈无活性胞质定位且SOD-1表达大幅降低,治疗中患者Nrf2活性核组分增加且SOD-1表达升高。
  • 在SH-SY5Y细胞中,多巴胺给药增加Nrf2核组分,可能作为该通路的诱导剂。

临床怎么用

  • 嗅黏膜神经元或可作为帕金森病生物标志物来源或疾病模型,辅助生物学分层。
  • 线粒体功能障碍和Nrf2/SOD-1通路是潜在治疗干预靶点。
  • 多巴胺可能通过增加Nrf2核转位诱导细胞保护通路,但需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The objective of this study was to outline the dynamics of the mitochondrial network and cytoprotective response in patients with Parkinson's disease (PD)-derived olfactory mucosa neurons (ONs) at different disease stages. METHODS: ONs obtained by nasal brush from 41 well-phenotyped patients with PD (n = 24 PD de novo [PDdn] and n = 17 under treatment [PDtr]) and 29 healthy controls were examined through real-time polymerase chain reaction (RT-PCR), immunofluorescence, and Western blot. An integrative set of experiments using SH-SY5Y neuronal cells was also performed. RESULTS: PD ONs accumulated α-synuclein oligomers in association with an aberrant subcellular distribution of mitochondrial markers COX IV and HSP60. DJ-1 ONs expression was permanently reduced in PD, revealing the mitochondrial dysfunction and justifying the defective Nrf2-mediated cytoprotective response. The Nrf2/SOD-1 pathway was indeed downregulated in PD ONs, although with stage-specific differences. In PDdn ONs, Nrf2 mostly presented in the inactive cytosolic localization with a major reduction of SOD-1 expression, whereas in PDtr, the Nrf2 active nuclear fraction increased, and the SOD-1 expression raised. In SH-SY5Y cells, we demonstrated that dopamine administration increases the Nrf2 nuclear fraction, acting as a possible pathway's inducer. INTERPRETATION: Human-derived ONs may recapitulate PD pathogenic milestones, exhibiting stage-specific interactions among α-synuclein oligomers, mitochondrial metabolism, and cytoprotective response. These findings highlighted mitochondrial dysfunction as a primary target for therapeutic interventions and a potential axis for the biological stratification of patients. Moreover, they supported the translational value of ONs, as a source of biomarkers or models, which is critical in the current changing paradigm of PD toward a biological-based approach. ANN NEUROL 2025;98:699-710.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Maftei D, Di Certo MG, Maurizi R, et al. α-Synuclein-Related Mitochondria-Nrf2 Dysfunction in Parkinson's Disease Olfactory Mucosa. Ann Neurol. 2025. PMID: 40503742. doi:10.1002/ana.27292

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。